Drug Trial Radar · NCT05104866
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
732
Actual
Start
Oct 18, 2021
Primary completion
Jul 24, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Nov 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.
Conditions
- Breast Cancer
Interventions
Dato-DXdDrug
Experimental drug. Provided in 100mg vials. IV infusion.
CapecitabineDrug
Tablet. Oral route of administration. Active comparator
GemcitabineDrug
IV Infusion. Active comparator
EribulinDrug
IV Infusion. Active comparator
VinorelbineDrug
IV Infusion. Active comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months
- Overall SurvivalTime frame: From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.
Locations
167 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California
Research Site
Los Angeles, California
Research Site
Palo Alto, California
Research Site
San Francisco, California
Research Site
Jacksonville, Florida
Research Site
Atlanta, Georgia
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Grand Rapids, Michigan
Research Site
New York, New York
Research Site
Cleveland, Ohio
Research Site
Portland, Oregon
Research Site
Nashville, Tennessee
Research Site
Richmond, Virginia
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
Anderlecht, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Itajaí, Brazil
Research Site
Jaú, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
North York, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Baoding, China
Research Site
Beijing, China
Research Site
Beijing, China
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.